Praxis Precision Medicines Inc
About
Praxis Precision Medicines Inc (NASDAQ:PRAX) — investor relations, events, news, and company updates on 6ix.
Latest News
Apr 14 2026
Praxis Precision Medicines Announces FDA Acceptance of New Drug Application for Ulixacaltamide HCl in Patients with Essential Tremor
Apr 6 2026
Praxis Precision Medicines Announces Positive Results from the EMBRAVE Part A Trial of Elsunersen in Patients with SCN2A Early-Onset Developmental and Epileptic Encephalopathy
Mar 30 2026
Praxis Precision Medicines Announces FDA Acceptance and Priority Review of New Drug Application for Relutrigine in Patients with SCN2A and SCN8A DEEs
Feb 19 2026
Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results
Feb 9 2026
Praxis Precision Medicines to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 19, 2026, and Participate in Upcoming Investor Conferences
Recent Videos
14 abril 26. Noticias acciones biotecnológicas. Resumen diario. #Español #Shorts #diario $XBI #bio
Apr 14, 2026
2026년 4월 1일 미 증시 제약·우주 항공 급등락 총정리 | APLS, CNTA, FLY, ALKS, PRAX 주요 뉴스
Mar 31, 2026
EMERALD Study Webinar
Mar 26, 2026
Praxis Precision Medicines, Inc. (PRAX) #Ulixacaltamide #Relutrigine #Vormatrigine #EssentialTremor
Mar 12, 2026
Financials
Revenue
$7.46 M
Market Cap
$8.92 B
EPS
-13.48